Early postmenopausal bone loss and intermittent cyclical etidronate therapy

Reviews in Contemporary Pharmacotherapy

Volumn 9, Issue 4, 1998, Pages 245-254

  Fogelman, I ^a   Blake, G ^a  

^a GUY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; ETIDRONIC ACID;

ADULT; BONE ATROPHY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; FEMALE; FEMUR; HORMONE SUBSTITUTION; HUMAN; META ANALYSIS; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; SPINE;

EID: 0031833625     PISSN: 09548602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (26)

1. Adachi JD, Benson WG, Brown J et al. Intermittent etidronate therapy to prevent corticosteroid induced osteoporosis. N Engl J Med 1997; 337: 382-387.
2. Anderson C, Cape RD, Crilly RG, Hodsman AB, Wolfe BM. Preliminary observations of a form of coherence therapy for osteoporosis. Calcif Tissue Int 1984; 26: 341-343.
3. Black DM, Cummings SR, Karpf DB et al. Randomised trial effect of alendronate on risk of fracture in women with existing verebral fractures. Lancet 1996; 348: 1535-1541.
4. Evans RA, Somers NM, Dunstan CR, Royle H, Kos S. The effect of low-dose cyclical etidronate and calcium on bone mass in early postmenopausal women. Osteoporosis Int 1993; 3: 71-75.
5. Frost HM. Treatment of osteoporosis by manipulation of coherent bone cell populations. Clin Orthop 1979; 143: 227-244.
6. Guncaga J, Lauffenburger T, Lentner C et al. Diphosphonate treatment of Paget's disease of bone: a correlated metabolic, calcium kinetic and morphometric study. Horm Metab Res 1974; 6: 62-69.
7. Harris ST, Watts NB, Jackson RD et al. Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy. Am J Med 1993; 95: 557-567.
8. Heaney SP, Saville PD. Etidronate disodium in postmenopausal osteoporosis. Clin Pharmacol Ther 1976; 20: 593-604.
9. Heath DA, Bullivant BG, Webber D, Pack S, Balena R. Effects of cyclical etidronate therapy in the prevention of bone loss in early postmenopausal women. J Bone Miner Res 1996; 11: S342.
10. Herd RJM, Balena R, Blake GM, Ryan PJ, Fogelman I. The prevention of early postmenopausal bone loss by cyclical etidronate therapy: a 2 year, double-blind, placebo-controlled study. Am J Med 1997; 103: 92-99.
11. Hesch RD, Heck J, Delling G et al. Results of a stipulatory therapy of low bone metablism in osteoporosis with (1-38)hPT and diphosphonate EHDP: protocol of study I, osteoporosis trial Hannover. Klin Wochenschr 1988; 66: 976-984.
12. Hodsman AB. Effects of cyclical therapy for osteoporosis using an oral regimen of inorganic phosphate and sodium etidronate: a clinical and bone histomorphometric study. Bone Miner 1989; 5: 201-212.
13. Mallette LE, LeBlanc AD, Pool JL, Mechanick JI. Cyclic therapy of osteoporosis with neutral phosphate and brief, high-dose pulses of etidronate. J Bone Miner Res 1989; 4: 143-148.
14. Meunier PJ, Confavreux E, Tupinon I, Hardouin C, Delman PD, Balena R. Prevention of early postmenopausal bone loss with cyclical etidronate therapy (a double-blind, placebo-controlled study and 1-year follow-up). J Clin Endocrinol Metab 1997; 82: 2784-2791.
15. Miller PD, Neal BJ, McIntyre DO, Yanover MJ, Anger MS, Kowalski L. Effect of cyclical etidronate therapy with phosphorus and etidronate on axial bone mineral density in postmenopausal osteoporotic women. Osteoporosis Int 1991; 1: 171-176.
16. Montessori MLM, Scheele WH, Netelembos JC, Kerkhoff JF, Bakker K. The use of etidronate and calcium versus calcium alone in the treatment of postmenopausal osteopenia: results of three years of treatment. Osteoporosis Int 1997; 7: 52-58.
17. Pacifici R, McMurty C, Vered I, Ruprich R, Avioli LV. Coherence therapy does not prevent axial bone loss in osteoporotic women: a preliminary comparative study. J Clin Endocrinol Metab 1988; 66: 747-753.
18. Pouilles JM, Trémollières F, Roux C et al. Cyclical etidronate for the prevention of early postmenopausal bone loss. Osteoporosis Int 1996; 6: 242.
19. Pouilles JM, Trémollières F, Roux C et al. Effects of cyclical etidronate therapy on bone loss in early postmenopausal women who are undergoing hormonal replacement therapy. Osteoporosis Int 1997; 7: 213-218.
20. Ryan PJ, Fogelman I. Clinical experience with etidronate in osteoporosis. Clin Rheumatol 1994; 13: 455-458.
21. Smith ML, Fogelman I, Hart DM, Scott E, Bevan J, Leggate I. Effect of etidronate disodium on bone turnover following surgical menopause. Calcif Tissue Int 1989; 44: 74-79.
22. Storm T, Thamsborg G, Steiniche T, Genent HK, Sørensen OH. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 1990; 322: 1265-1271.
23. Storm T, Thamsborg G, Kollerup G et al. Five years of intermittent, cyclical etidronate therapy increases bone mass and reduces vertebral fracture rate in postmenopausal osteoporosis. Bone Min 1992; 17 (Suppl 1): 157.
24. Storm T, Kollerup G, Thamsborg G, Genant HK, Sørensen OH. Five years of clinical experience with intermittent cyclical etidronate for postmenopausal osteoporosis. J Rheumatol 1996; 23: 1560-1564.
25. Tobias JH, Dalzell N, Pazianas M, Chambers TJ. Cyclical etidronate prevents spinal bone loss in early postmenopausal women. Br J Rheumatol 1997; 36: 612-613.
26. Watts NB, Harsi ST, Genant HK. et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 1990; 323: 73-79.